

## THERAPIES AND DIAGNOSTICS FOR CERVICAL CANCER



HLC141A  
August 2013

Usha Nagavarapu  
*Project Analyst*

ISBN: 1-56965-523-5

**bcc** | Research  
Market Forecasting

**BCC Research**  
49 Walnut Park, Building 2  
Wellesley, MA 02481 USA  
866-285-7215 (toll-free within the USA),  
or (+1) 781-489-7301  
[www.bccresearch.com](http://www.bccresearch.com)  
[information@bccresearch.com](mailto:information@bccresearch.com)

**TABLE OF CONTENTS**

<b>TOPIC</b>	<b>PAGE NO.</b>
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
INTENDED AUDIENCE	2
SCOPE OF THE STUDY	3
METHODOLOGY	3
INFORMATION SOURCES	4
ABOUT THE AUTHOR	4
RELATED BCC REPORTS	4
BCC ONLINE SERVICES	4
DISCLAIMER	5
CHAPTER 2 SUMMARY	7
SUMMARY	7
<i>SUMMARY TABLE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 (\$ MILLIONS)</i>	7
<i>SUMMARY FIGURE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 (\$ MILLIONS)</i>	8
CHAPTER 3 OVERVIEW	10
<i>TABLE 1 MAIN TYPES OF CANCER AND MORTALITY</i>	10
<i>FIGURE 1 MAIN TYPES OF CANCER AND MORTALITY</i>	10
<i>TABLE 2 CANCER: KEY FACTS</i>	11
<i>TABLE 3 PREVENTION STRATEGIES</i>	11
EARLY DETECTION	12
EARLY DIAGNOSIS	12
SCREENING	12
<i>TABLE 4 CURRENT SCREENING METHODS</i>	12
CANCER TREATMENT	12
<i>TABLE 5 NONCOMMUNICABLE DISEASES ACTION PLAN</i>	13
CERVICAL CANCER	13
<i>TABLE 6 HISTORY</i>	14
CERVICAL CANCER RESEARCH AND TREATMENT	14
SENTINEL LYMPH NODE BIOPSY	14
HUMAN PAPILLOMAVIRUS (HPV) VACCINES	14
TARGETED THERAPY	15
HYPERTHERMIA	15
DRUG TREATMENT OF PRECANCERS	15
SYMPTOMS	16
<i>TABLE 7 CERVICAL CANCER SYMPTOMS</i>	16
<i>TABLE 8 ADVANCED CERVICAL CANCER SYMPTOMS</i>	16
DIAGNOSIS	16
<i>TABLE 9 DIAGNOSIS OF CERVICAL CANCER</i>	17
<i>TABLE 10 RISK FACTORS FOR CERVICAL CANCER</i>	17
TREATMENT	18
<i>TABLE 11 CERVICAL CANCER STAGING</i>	18

<b>TOPIC</b>	<b>PAGE NO.</b>
PROGNOSIS	19
CHAPTER 4 CERVICAL CANCER: BIOLOGY	21
CERVIX	21
CAUSES	21
HUMAN PAPILLOMAVIRUS	22
<i>TABLE 12 HUMAN PAPILLOMAVIRUS: TYPES</i>	23
SYMPTOMS OF GENITAL WARTS	24
HUMAN PAPILLOMAVIRUS (HPV) INFECTIONS AND TRANSMISSION	24
E6/E7 PROTEINS	26
VACCINES	28
TREATMENT OF GENITAL WARTS	29
CANCER SUBTYPES	29
<i>TABLE 13 HISTOLOGIC SUBTYPES OF INVASIVE CERVICAL CARCINOMA</i>	30
<i>TABLE 14 NON-CARCINOMA MALIGNANCIES THAT CAN RARELY OCCUR IN THE CERVIX</i>	30
NOVEL BIOMARKERS IN CERVICAL CANCER PREVENTION	30
E6/E7 MESSENGER RNA (MRNA) DETECTION	30
P16INK4A	30
OTHER BIOMARKERS	31
EPIGENETIC MARKERS: DNA METHYLATION	31
VIRAL METHYLATION	31
CHROMOSOMAL ABNORMALITIES	32
MICRORNAS (MIRNAS)	32
BIOMARKERS AND THE FUTURE	33
CHAPTER 5 SCREENING	35
WHY SCREENING IS CRITICAL	35
CERVICAL CANCER SCREENING GUIDELINES	36
VACCINATION	36
CERVICAL CANCER DIAGNOSIS	36
EXAMINATION	37
COMPUTED TOMOGRAPHY	37
BIOPSY	38
PRECANCEROUS LESIONS	38
CLINICAL STAGING	39
<i>TABLE 15 THE MAJOR CATEGORIES OF THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) CLASSIFICATION</i>	39
LYMPH NODE EVALUATION	39
<i>TABLE 16 THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) STAGES</i>	40
Additional Staging	40
LIMITATIONS OF TECHNIQUES	40
CERVICAL CANCER SCREENING	41
<i>TABLE 17 TWO SCREENING TESTS THAT HELP PREVENT CERVICAL CANCER OR DETECT IT EARLY</i>	41
PAP TEST	41
<i>TABLE 18 TYPES OF SCREENING FOR CERVICAL CANCER</i>	43

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 19 PAP TEST INDICATIONS</i>	43
<i>TABLE 20 BETHESDA SYSTEM</i>	45
Pap Tests: Issues	45
HUMAN PAPILLOMAVIRUS (HPV) TEST	45
Tests and Challenges	46
Procedure and Current Status	46
FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS	47
<i>TABLE 21 FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS</i>	47
Digene Hybrid Capture 2 (HC2) High-Risk HPV DNA Test	47
Cervista HPV HR and Genfind DNA Extraction Kit	48
Cervista HPV 16/18	48
cobas Human Papillomavirus (HPV) Test	48
APTIMA Human Papillomavirus (HPV) Assay	49
DIAGNOSTIC TESTS	49
Colposcopy	49
Cervical Biopsies	50
Colposcopic Biopsy	50
Endocervical Curettage (Endocervical Scraping)	50
Cone Biopsy	50
CYSTOSCOPY, PROCTOSCOPY, AND EXAMINATION UNDER ANESTHESIA	51
IMAGING STUDIES	51
CERVICAL CANCER SCREENING GUIDELINES	52
<i>TABLE 22 CERVICAL CANCER SCREENING</i>	52
CERVICAL CANCER SCREENING	53
Total Hysterectomy and Pap Tests: Issues	53
<i>TABLE 23 THE ACS-ASCCP-ASCP RECOMMENDATIONS: CHANGES FROM THE PREVIOUS ACS GUIDELINES</i>	54
TYPES OF GYNECOLOGIC TUMOR MARKERS	54
<i>TABLE 24 IMPORTANT GYNECOLOGIC TUMOR MARKERS</i>	55
<i>TABLE 25 OTHER POTENTIAL GYNECOLOGIC TUMOR MARKERS</i>	55
CLINICAL USEFULNESS OF TUMOR MARKERS	56
CONCLUSION	56
CHAPTER 6 THE TREATMENT OF CERVICAL CANCER	58
CLINICAL STAGES AND PROGNOSIS	58
TREATMENT	58
RISK FACTORS	58
SCREENING PROGRAMS	58
CYTOLOGIC TESTS	59
CONVENTIONAL CYTOLOGY	59
CLASSIFICATION SYSTEM	59
<i>TABLE 26 THE BETHESDA SYSTEM</i>	60
CERVICAL CANCER TREATMENT STRATEGIES	61
CERVICAL CANCER OVERVIEW	62
STAGE-BASED THERAPY	62
Stage 0 Cancer	62
Stage IA1 Cancer	62
Stage IA2, IB, or IIA Cancer	62

<b>TOPIC</b>	<b>PAGE NO.</b>
Stage IIB, III, or IVA Cancer	63
Stage IVB and Recurrent Cancer	63
COMPLICATIONS OF THERAPY	64
Radiation-Related Complications	64
Problems Due to Surgeries	64
THERAPEUTIC STRATEGY	64
<i>TABLE 27 DRUGS APPROVED TO TREAT CERVICAL CANCER</i>	65
Chemotherapy	65
<i>TABLE 28 COMMON CHEMOTHERAPY MEDICINES USED TO TREAT CERVICAL CANCER</i>	65
Cisplatin	66
Ifosfamide (Ifex)	66
Fluorouracil (Acrucil)	66
Paclitaxel (Taxol)	66
Topotecan (Hycamtin)	66
Docetaxel	66
Gemcitabine	68
Vaccines: Inactivated, Viral	68
Human Papillomavirus Vaccine, Quadrivalent (Gardasil)	69
Human Papillomavirus Vaccine, Bivalent (Cervarix)	69
NEW AND PROMISING THERAPIES	69
DRUGS IN CLINICAL TRIALS	70
Ixabepilone	70
ADXS11-001	70
ISA101 Vaccine	70
Veliparib	70
Carcinoembryonic Antigen (CEA)	71
Olaparib	71
CHAPTER 7 CERVICAL CANCER INCIDENCE	73
CANCER WORLDWIDE-THE GLOBAL PICTURE	73
<i>TABLE 29 POPULATION MEASURES AND CANCER INCIDENCE AND MORTALITY IN REGIONS OF THE WORLD, ESTIMATES 2008-2010</i>	75
COMMON CANCERS	76
<i>TABLE 30 TOTAL NUMBER AND PERCENTAGES OF ALL CANCER DEATHS, WORLDWIDE, 2008</i>	77
FUTURE TRENDS	77
<i>TABLE 31 THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED CANCER INCIDENCE RATES PER 100,000 POPULATION, U.K., 2007-2030</i>	79
GLOBAL INCIDENCE OF CERVICAL CANCER	79
<i>TABLE 32 POPULATION ATTRIBUTABLE FRACTION (%)</i>	80
<i>TABLE 33 CERVICAL CANCER: GLOBAL INCIDENCE, 2008</i>	81
<i>TABLE 34 GLOBAL CERVICAL CANCER: MORTALITY 2008 AND 2030*</i>	82
RECENT BREAKTHROUGHS	83
<i>TABLE 35 WORLDWIDE PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) IN WOMEN WITH CERVICAL CANCER</i>	83
CERVICAL CANCER THROUGH TIME	84
<i>TABLE 36 CERVICAL CANCER BY CONTINENTS, 2008 ESTIMATES</i>	85

<b>TOPIC</b>	<b>PAGE NO.</b>
TABLE 37 CERVICAL CANCER WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION, FEMALES IN WORLD REGIONS, 2008 ESTIMATES	85
TABLE 38 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)	86
FIGURE 2 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)	86
TABLE 39 WORLDWIDE BURDEN OF CERVICAL CANCER BY AREA, 2008	89
TABLE 40 CHANGING TRENDS IN CANCER-SPECIFIC AGE-ADJUSTED INCIDENCE (%)	90
PREVENTION STRATEGIES	93
CERVICAL CANCER AND THE U.S.	94
TABLE 41 U.S.: ESTIMATED NEW CASES AND DEATHS FROM CERVICAL (UTERINE CERVIX) CANCER, 2012 AND 2013	94
INCIDENCE AND MORTALITY	94
TABLE 42 U.S.: INCIDENCE RATES BY RACE, 2005-2009	95
U.S. Cervical Cancer Mortality	95
TABLE 43 U.S.: DEATH RATES BY RACE, 2005-2009	95
Survival and Stage	96
TABLE 44 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, ALL RACES, FEMALES, 2002-2008	96
TABLE 45 FIVE-YEAR OBSERVED SURVIVAL RATE	97
European Union	97
TABLE 46 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES	98
FIGURE 3 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES	98
U.K.	100
TABLE 47 NUMBER OF NEW CASES AND CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2009	100
TABLE 48 CERVICAL CANCER: AVERAGE NUMBER OF NEW CASES PER YEAR AND AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2007-2009	101
TABLE 49 CERVICAL CANCER: PERCENTAGE CHANGE IN AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2008-2009	102
TABLE 50 CERVICAL CANCER: ONE-YEAR, FIVE-YEAR, AND 10-YEAR CANCER PREVALENCE AMONG FEMALES IN U.K., DECEMBER 31, 2006	102
TABLE 51 NUMBER OF NEW CASES IN U.K., 2009 AND 2010	103
TABLE 52 U.K.: THE 10 MOST COMMONLY DIAGNOSED CANCERS IN FEMALES IN 1984, 2007, AND 2030	104
TABLE 53 CERVICAL CANCER: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION IN U.K., 2010 AND 2030	104
TABLE 54 U.K.: THE 10 MOST COMMON CAUSES OF CANCER DEATH IN FEMALES IN 1990, 2010, AND 2030	105
India	106
China	107
Africa	108
TABLE 55 KEY STATISTICS IN AFRICA AND ITS REGIONS, 2008	109
TABLE 56 HUMAN PAPILOMAVIRUS (HPV) PREVALENCE IN THE GENERAL POPULATION, 2008	110

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 57 AFRICA: PREVALENCE HPV 16 AND/OR HPV 18 AMONG WOMEN WITH THE FOLLOWING CHARACTERISTICS</i>	110
<i>TABLE 58 INCIDENCE OF CERVICAL CANCER IN AFRICA BY REGION, 2008</i>	111
<i>TABLE 59 MORTALITY OF CERVICAL CANCER IN AFRICA BY REGION, 2008</i>	111
<i>TABLE 60 AGE-STANDARDIZED INCIDENCE RATES OF CERVICAL CANCER IN AFRICA, 2008</i>	111
<i>TABLE 61 AGE-STANDARDIZED MORTALITY RATES OF CERVICAL CANCER IN AFRICA, 2008</i>	112
SCREENING AND TREATMENT APPROACHES	112
SAUDI ARABIA	113
NIGERIA	113
KENYA	114
GAMBIA	116
CANADA	116
GERMANY	116
<i>TABLE 62 INCIDENCE OF CERVICAL CANCER IN GERMANY, WESTERN EUROPE, AND THE WORLD, 2008 (RATES PER 100,000 WOMEN PER YEAR)</i>	117
<i>TABLE 63 KEY STATISTICS ON GERMANY, 2010-2025</i>	117
AUSTRALIA	117
<i>TABLE 64 AUSTRALIA: PROJECTED COMMON CANCERS IN FEMALES, 2020</i>	118
<i>TABLE 65 AUSTRALIA: PROJECTED NUMBER OF NEW CERVICAL CANCER CASES AND AGE-STANDARDIZED RATES AMONG FEMALES WITH 95% PREDICTION INTERVALS, 2011-2020</i>	119
<i>TABLE 66 AUSTRALIA: PROJECTED CERVICAL CANCER STATISTICS, 2020</i>	119
HONG KONG	119
CONCLUSION	120
CHAPTER 8 CERVICAL CANCER DIAGNOSTICS MARKET	123
<i>TABLE 67 WOMEN UNDERGOING CERVICAL CANCER SCREENING</i>	123
CERVICAL CANCER SCREENING	123
CERVICAL CANCER TESTING GUIDELINES	124
CERVICAL CANCER DIAGNOSTIC TESTS MARKET	125
<i>TABLE 68 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, THROUGH 2018 (\$ MILLIONS)</i>	125
<i>FIGURE 4 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, 2012-2018 (\$ MILLIONS)</i>	125
MARKET DRIVERS	126
<i>TABLE 69 MARKET DRIVERS</i>	126
<i>TABLE 70 KEY PLAYERS</i>	127
RESTRAINTS	127
Lack of Appropriate Health Care Infrastructure in Underdeveloped and Developing Countries	128
HPV VACCINATION	129
Available Vaccines	129
WHO Recommends the Vaccine for Girls Between the Ages of 10 and 13	130
WHO Does Not Recommend the Vaccine for Boys	130
CERVICAL CANCER DIAGNOSTIC TESTS MARKET BY TEST TYPES	131
Pap Smear Test	131

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 71 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	131
<i>FIGURE 5 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	131
<i>TABLE 72 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (MILLIONS)</i>	133
Pap Tests: U.S.	133
<i>TABLE 73 U.S.: PERCENT OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 (%)</i>	133
<i>TABLE 74 U.S.: PERCENT OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010 (%)</i>	134
<i>TABLE 75 PAP TESTS ORDERED OR PROVIDED IN U.S., 2010</i>	134
<i>TABLE 76 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT DEPARTMENT VISITS IN U.S., 2010</i>	135
Latest Technology	135
Canadian Market	136
Ontario Guidelines	136
Cervical Cancer and India	136
PAP TESTS: BENEFIT OR NOT?	137
<i>TABLE 77 ABNORMALITIES OF THE CERVIX</i>	138
GLOBAL COLPOSCOPY TESTS MARKET	138
<i>TABLE 78 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)</i>	139
<i>FIGURE 6 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)</i>	139
<i>TABLE 79 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	140
<i>FIGURE 7 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	140
<i>TABLE 80 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., THROUGH 2018 (\$ MILLIONS)</i>	140
<i>FIGURE 8 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., 2012-2018 (\$ MILLIONS)</i>	141
Biopsy	142
Types of Cervical Biopsies	142
<i>TABLE 81 TYPES OF CERVICAL BIOPSIES</i>	142
ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET	143
<i>TABLE 82 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	144
<i>FIGURE 9 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	144
Femasys	144
Liquid-Based Cytology	145
HPV TESTING	145
<i>TABLE 83 WORLDWIDE HUMAN PAPILOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	146
<i>FIGURE 10 WORLDWIDE HUMAN PAPILOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	146
<i>TABLE 84 KEY PLAYERS</i>	147
CURRENT MOLECULAR DIAGNOSTIC TESTS FOR HUMAN PAPILOMAVIRUS (HPV)	148



<b>TOPIC</b>	<b>PAGE NO.</b>
A NEW APPROACH: MESSENGER RNA (MRNA)-BASED DETECTION OF E6/E7 ONCOPROTEINS	148
bioMerieux's Test	148
Roche	149
Innovative Cervical Screening Application Launches in the U.K., and Ireland	150
Quest Diagnostics	150
OncoHealth	151
QIAGEN/Digene	152
Trovagene	152
Becton, Dickinson and Co.: Human Papillomavirus (HPV) Testing and Issues	152
NEW DEVICES	153
Zilico	153
LUMA Cervical Imaging System	154
CHAPTER 9 CERVICAL CANCER PROPHYLACTICS MARKET	156
CERVICAL CANCER VACCINES	156
TABLE 85 VACCINES FOR PREVENTION OF CERVICAL CANCER	156
COMPETITION	156
CERVICAL CANCER PROPHYLACTICS MARKET	157
Preventative Vaccines	157
TABLE 86 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	157
FIGURE 11 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	157
Vaccine Market: Leaders	158
TABLE 87 KEY COMPANIES: CERVICAL VACCINE MARKET REVENUES AND FORECAST, 2011 AND 2018 (\$ MILLIONS)	158
GLOBAL CANCER VACCINES MARKET	159
TABLE 88 GLOBAL VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	159
TABLE 89 KEY COMPANIES	159
CANCER VACCINE MARKET: U.S.	160
TABLE 90 U.S. VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	160
PROPHYLACTIC VACCINES	160
PROPHYLACTIC CANCER VACCINES MARKET	160
Cervarix	161
TABLE 91 GLOBAL CERVARIX SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	161
FIGURE 12 GLOBAL CERVARIX SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	162
Gardasil	162
TABLE 92 GARDASIL SALES AND FORECAST, 2012 AND 2013 (\$ MILLIONS)	163
FIGURE 13 GARDASIL SALES AND FORECAST, 2012 AND 2013 (\$ MILLIONS)	163
NEW PRODUCTS	164
VS03	164
TABLE 93 V503 SALES AND FORECAST, 2013 AND 2018 (\$ MILLIONS)	164
LATEST DEVELOPMENTS	164
U.K. to Drop Cervarix	164

<b>TOPIC</b>	<b>PAGE NO.</b>
Cancer Vaccines in Poor Nations	164
CONCLUSIONS	165
CHAPTER 10 THERAPEUTIC MARKET	168
<i>TABLE 94 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 (\$ MILLIONS)</i>	168
<i>FIGURE 14 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 (\$ MILLIONS)</i>	168
TREATMENT OF CERVICAL CANCER	169
<i>TABLE 95 TYPES OF SURGERY FOR EARLY CERVICAL CANCER</i>	169
CHEMOTHERAPY MARKET	170
CANCER TREATMENT MARKET	170
CANCER THERAPY	171
<i>TABLE 96 MAJOR PLAYERS</i>	172
Cancer Costs in the U.S.	172
<i>TABLE 97 KEY FACTS: CANCER IN U.S., 2020</i>	172
<i>TABLE 98 U.S.: CERVICAL CANCER PREVALENCE ESTIMATES FOR 2010 AND 2020 (THOUSANDS)</i>	173
<i>TABLE 99 CERVICAL CANCER: CANCER PREVALENCE IN U.S.</i>	173
<i>TABLE 100 CANCER CARE COST IN U.S., 2010 AND 2020 (\$ BILLIONS)</i>	174
CYTOTOXIC THERAPIES MARKET	174
<i>TABLE 101 CYTOTOXIC THERAPIES MARKET INDICATIONS</i>	175
<i>TABLE 102 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)</i>	175
<i>FIGURE 15 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)</i>	176
<i>TABLE 103 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	176
<i>FIGURE 16 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	176
<i>TABLE 104 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	177
<i>FIGURE 17 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	178
<i>TABLE 105 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)</i>	178
<i>FIGURE 18 JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)</i>	179
CERVICAL CHEMOTHERAPY MARKET	179
<i>TABLE 106 CERVICAL CANCER CHEMOTHERAPY MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 (\$ MILLIONS)</i>	179
<i>FIGURE 19 CERVICAL CANCER MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 (\$ MILLIONS)</i>	179
<i>TABLE 107 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	180
<i>FIGURE 20 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	181
CHEMOTHERAPY AND DRAWBACKS	181
DRUGS USED IN CHEMOTHERAPY	181
<i>TABLE 108 DRUGS APPROVED TO TREAT CERVICAL CANCER</i>	181
Paclitaxel	181
<i>TABLE 109 SALES OF KEY DRUGS FOR CERVICAL CANCER, 2010 (\$ MILLIONS)</i>	182
Carboplatin	182
<i>TABLE 110 CARBOPLATIN SALES, 2010-2012 (\$ MILLIONS)</i>	182
Taxotere/Docetaxel	182
<i>TABLE 111 TAXOTERE GLOBAL SALES AND FORECAST, 2010-2012 (\$ MILLIONS)</i>	183
Gemzar	183

<b>TOPIC</b>	<b>PAGE NO.</b>
<i>TABLE 112 GEMZAR REVENUE, 2010 AND 2011 (\$ MILLIONS)</i>	184
Future for Gemcitabine as a Drug	184
Cisplatin	185
Hycamtin	185
<i>TABLE 113 HYCAMTIN SALES, 2010-2012 (\$ MILLIONS)</i>	186
Bleomycin	186
OTHER TREATMENT DRUGS	186
Avastin	186
<i>TABLE 114 AVASTIN SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	187
CANCER IMMUNOTHERAPY	188
TREATMENT STRATEGIES	189
<i>TABLE 115 CERVICAL CANCER: TREATMENT OPTIONS, 1999-2008 (%)</i>	189
TREATMENT PROCEDURE COST ESTIMATES	190
CERVICAL CANCER SURGERY	191
<i>TABLE 116 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	191
<i>FIGURE 21 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	192
COSTS OF CERVICAL CANCER SURGERY	192
<i>TABLE 117 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	193
<i>FIGURE 22 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	193
<i>TABLE 118 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	194
<i>FIGURE 23 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	194
RADIATION THERAPY FOR CERVICAL CANCER	195
Radiation Therapy and Cost Estimates	195
<i>TABLE 119 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	196
<i>FIGURE 24 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL-SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	196
<i>TABLE 120 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)</i>	197
<i>FIGURE 25 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)</i>	197
CONCLUSIONS	197
<i>TABLE 121 KEY FACTS ABOUT CERVICAL CANCER</i>	198
CHAPTER 11 PATENT LANDSCAPE	201
<i>TABLE 122 CERVICAL CANCER VACCINE PATENTS (%)</i>	201
GLOBAL IMPACT OF PATENT EXPIRIES	201
PATENT LANDSCAPE	202
Hycamtin (Topotecan Hydrochloride)	203
Gemzar	203
<i>TABLE 123 CERVICAL CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY</i>	203
Doxil	204
Cisplatin	204

<b>TOPIC</b>	<b>PAGE NO.</b>
Avastin	204
CHAPTER 12 SELECTED COMPANY PROFILES	206
ABBOTT LABORATORIES	206
ADVAXIS	206
ASTRAZENECA	206
BECTON, DICKENSON AND CO.	207
BRISTOL-MYERS SQUIBB	207
DIGENE CORP.	207
DENDREON CORP.	208
FEMASYS	208
GLAXOSMITHKLINE	208
HOLOGIC	208
ISA PHARMACEUTICALS	209
JOHNSON & JOHNSON	209
MERCK	210
ONCOHEALTH CORP.	210
PFIZER	210
QUEST DIAGNOSTICS	211
QIAGEN	212
ROCHE DIAGNOSTICS	212
SANOFI	212
TAJ PHARMACEUTICALS	213
TEVA PHARMACEUTICAL INDUSTRIES	213
TROVAGENE	213
ZILICO LTD.	214
CHAPTER 13 REFERENCES	216

**LIST OF TABLES**

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
SUMMARY TABLE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, THROUGH 2018 (\$ MILLIONS)	7
TABLE 1 MAIN TYPES OF CANCER AND MORTALITY	10
TABLE 2 CANCER: KEY FACTS	11
TABLE 3 PREVENTION STRATEGIES	11
TABLE 4 CURRENT SCREENING METHODS	12
TABLE 5 NONCOMMUNICABLE DISEASES ACTION PLAN	13
TABLE 6 HISTORY	14
TABLE 7 CERVICAL CANCER SYMPTOMS	16
TABLE 8 ADVANCED CERVICAL CANCER SYMPTOMS	16
TABLE 9 DIAGNOSIS OF CERVICAL CANCER	17
TABLE 10 RISK FACTORS FOR CERVICAL CANCER	17
TABLE 11 CERVICAL CANCER STAGING	18
TABLE 12 HUMAN PAPILLOMAVIRUS: TYPES	23
TABLE 13 HISTOLOGIC SUBTYPES OF INVASIVE CERVICAL CARCINOMA	30
TABLE 14 NON-CARCINOMA MALIGNANCIES THAT CAN RARELY OCCUR IN THE CERVIX	30
TABLE 15 THE MAJOR CATEGORIES OF THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) CLASSIFICATION	39
TABLE 16 THE INTERNATIONAL FEDERATION OF GYNECOLOGY AND OBSTETRICS (FIGO) STAGES	40
TABLE 17 TWO SCREENING TESTS THAT HELP PREVENT CERVICAL CANCER OR DETECT IT EARLY	41
TABLE 18 TYPES OF SCREENING FOR CERVICAL CANCER	43
TABLE 19 PAP TEST INDICATIONS	43
TABLE 20 BETHESDA SYSTEM	45
TABLE 21 FDA-APPROVED HUMAN PAPILLOMAVIRUS (HPV) TESTS	47
TABLE 22 CERVICAL CANCER SCREENING	52
TABLE 23 THE ACS-ASCCP-ASCP RECOMMENDATIONS: CHANGES FROM THE PREVIOUS ACS GUIDELINES	54
TABLE 24 IMPORTANT GYNECOLOGIC TUMOR MARKERS	55
TABLE 25 OTHER POTENTIAL GYNECOLOGIC TUMOR MARKERS	55
TABLE 26 THE BETHESDA SYSTEM	60
TABLE 27 DRUGS APPROVED TO TREAT CERVICAL CANCER	65
TABLE 28 COMMON CHEMOTHERAPY MEDICINES USED TO TREAT CERVICAL CANCER	65
TABLE 29 POPULATION MEASURES AND CANCER INCIDENCE AND MORTALITY IN REGIONS OF THE WORLD, ESTIMATES 2008-2010	75
TABLE 30 TOTAL NUMBER AND PERCENTAGES OF ALL CANCER DEATHS, WORLDWIDE, 2008	77
TABLE 31 THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED CANCER INCIDENCE RATES PER 100,000 POPULATION, U.K., 2007-2030	79
TABLE 32 POPULATION ATTRIBUTABLE FRACTION (%)	80
TABLE 33 CERVICAL CANCER: GLOBAL INCIDENCE, 2008	81
TABLE 34 GLOBAL CERVICAL CANCER: MORTALITY 2008 AND 2030*	82
TABLE 35 WORLDWIDE PREVALENCE OF HUMAN PAPILLOMAVIRUS (HPV) IN WOMEN WITH CERVICAL CANCER	83
TABLE 36 CERVICAL CANCER BY CONTINENTS, 2008 ESTIMATES	85

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 37 CERVICAL CANCER WORLD AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION, FEMALES IN WORLD REGIONS, 2008 ESTIMATES	85
TABLE 38 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)	86
TABLE 39 WORLDWIDE BURDEN OF CERVICAL CANCER BY AREA, 2008	89
TABLE 40 CHANGING TRENDS IN CANCER-SPECIFIC AGE-ADJUSTED INCIDENCE (%)	90
TABLE 41 U.S.: ESTIMATED NEW CASES AND DEATHS FROM CERVICAL (UTERINE CERVIX) CANCER, 2012 AND 2013	94
TABLE 42 U.S.: INCIDENCE RATES BY RACE, 2005-2009	95
TABLE 43 U.S.: DEATH RATES BY RACE, 2005-2009	95
TABLE 44 STAGE DISTRIBUTION AND FIVE-YEAR RELATIVE SURVIVAL BY STAGE AT DIAGNOSIS, ALL RACES, FEMALES, 2002-2008	96
TABLE 45 FIVE-YEAR OBSERVED SURVIVAL RATE	97
TABLE 46 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES	98
TABLE 47 NUMBER OF NEW CASES AND CRUDE AND EUROPEAN AGE-STANDARDIZED (AS) INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2009	100
TABLE 48 CERVICAL CANCER: AVERAGE NUMBER OF NEW CASES PER YEAR AND AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2007-2009	101
TABLE 49 CERVICAL CANCER: PERCENTAGE CHANGE IN AGE-SPECIFIC INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES IN U.K., 2008-2009	102
TABLE 50 CERVICAL CANCER: ONE-YEAR, FIVE-YEAR, AND 10-YEAR CANCER PREVALENCE AMONG FEMALES IN U.K., DECEMBER 31, 2006	102
TABLE 51 NUMBER OF NEW CASES IN U.K., 2009 AND 2010	103
TABLE 52 U.K.: THE 10 MOST COMMONLY DIAGNOSED CANCERS IN FEMALES IN 1984, 2007, AND 2030	104
TABLE 53 CERVICAL CANCER: THE PROJECTED PERCENTAGE CHANGE IN EUROPEAN AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION IN U.K., 2010 AND 2030	104
TABLE 54 U.K.: THE 10 MOST COMMON CAUSES OF CANCER DEATH IN FEMALES IN 1990, 2010, AND 2030	105
TABLE 55 KEY STATISTICS IN AFRICA AND ITS REGIONS, 2008	109
TABLE 56 HUMAN PAPILLOMAVIRUS (HPV) PREVALENCE IN THE GENERAL POPULATION, 2008	110
TABLE 57 AFRICA: PREVALENCE HPV 16 AND/OR HPV 18 AMONG WOMEN WITH THE FOLLOWING CHARACTERISTICS	110
TABLE 58 INCIDENCE OF CERVICAL CANCER IN AFRICA BY REGION, 2008	111
TABLE 59 MORTALITY OF CERVICAL CANCER IN AFRICA BY REGION, 2008	111
TABLE 60 AGE-STANDARDIZED INCIDENCE RATES OF CERVICAL CANCER IN AFRICA, 2008	111
TABLE 61 AGE-STANDARDIZED MORTALITY RATES OF CERVICAL CANCER IN AFRICA, 2008	112
TABLE 62 INCIDENCE OF CERVICAL CANCER IN GERMANY, WESTERN EUROPE, AND THE WORLD, 2008 (RATES PER 100,000 WOMEN PER YEAR)	117
TABLE 63 KEY STATISTICS ON GERMANY, 2010-2025	117
TABLE 64 AUSTRALIA: PROJECTED COMMON CANCERS IN FEMALES, 2020	118
TABLE 65 AUSTRALIA: PROJECTED NUMBER OF NEW CERVICAL CANCER CASES AND AGE-STANDARDIZED RATES AMONG FEMALES WITH 95% PREDICTION INTERVALS, 2011-2020	119
TABLE 66 AUSTRALIA: PROJECTED CERVICAL CANCER STATISTICS, 2020	119

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 67 WOMEN UNDERGOING CERVICAL CANCER SCREENING	123
TABLE 68 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, THROUGH 2018 (\$ MILLIONS)	125
TABLE 69 MARKET DRIVERS	126
TABLE 70 KEY PLAYERS	127
TABLE 71 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	131
TABLE 72 NUMBER OF PAP SMEAR TESTS PERFORMED IN THE U.S. AND EUROPE, 2012 AND 2013 (MILLIONS)	133
TABLE 73 U.S.: PERCENT OF PAP SMEAR TESTS PERFORMED, 2008 AND 2010 (%)	133
TABLE 74 U.S.: PERCENT OF WOMEN WHO RECEIVE PAP SMEAR TESTS, AGE-STRATIFIED, 2008 AND 2010 (%)	134
TABLE 75 PAP TESTS ORDERED OR PROVIDED IN U.S., 2010	134
TABLE 76 PAP TESTS ORDERED OR PROVIDED AT OUTPATIENT DEPARTMENT VISITS IN U.S., 2010	135
TABLE 77 ABNORMALITIES OF THE CERVIX	138
TABLE 78 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)	139
TABLE 79 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, THROUGH 2018 (\$ MILLIONS)	140
TABLE 80 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., THROUGH 2018 (\$ MILLIONS)	140
TABLE 81 TYPES OF CERVICAL BIOPSIES	142
TABLE 82 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	144
TABLE 83 WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	146
TABLE 84 KEY PLAYERS	147
TABLE 85 VACCINES FOR PREVENTION OF CERVICAL CANCER	156
TABLE 86 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	157
TABLE 87 KEY COMPANIES: CERVICAL VACCINE MARKET REVENUES AND FORECAST, 2011 AND 2018 (\$ MILLIONS)	158
TABLE 88 GLOBAL VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	159
TABLE 89 KEY COMPANIES	159
TABLE 90 U.S. VACCINE MARKET: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	160
TABLE 91 GLOBAL CERVARIX SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	161
TABLE 92 GARDASIL SALES AND FORECAST, 2012 AND 2013 (\$ MILLIONS)	163
TABLE 93 V503 SALES AND FORECAST, 2013 AND 2018 (\$ MILLIONS)	164
TABLE 94 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 (\$ MILLIONS)	168
TABLE 95 TYPES OF SURGERY FOR EARLY CERVICAL CANCER	169
TABLE 96 MAJOR PLAYERS	172
TABLE 97 KEY FACTS: CANCER IN U.S., 2020	172
TABLE 98 U.S.: CERVICAL CANCER PREVALENCE ESTIMATES FOR 2010 AND 2020 (THOUSANDS)	173
TABLE 99 CERVICAL CANCER: CANCER PREVALENCE IN U.S.	173
TABLE 100 CANCER CARE COST IN U.S., 2010 AND 2020 (\$ BILLIONS)	174

<b>TABLE HEADING</b>	<b>PAGE NO.</b>
TABLE 101 CYTOTOXIC THERAPIES MARKET INDICATIONS	175
TABLE 102 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	175
TABLE 103 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	176
TABLE 104 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	177
TABLE 105 JAPANESE CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	178
TABLE 106 CERVICAL CANCER CHEMOTHERAPY MARKET: GLOBAL REVENUE AND FORECASTS, THROUGH 2018 (\$ MILLIONS)	179
TABLE 107 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	180
TABLE 108 DRUGS APPROVED TO TREAT CERVICAL CANCER	181
TABLE 109 SALES OF KEY DRUGS FOR CERVICAL CANCER, 2010 (\$ MILLIONS)	182
TABLE 110 CARBOPLATIN SALES, 2010-2012 (\$ MILLIONS)	182
TABLE 111 TAXOTERE GLOBAL SALES AND FORECAST, 2010-2012 (\$ MILLIONS)	183
TABLE 112 GEMZAR REVENUE, 2010 AND 2011 (\$ MILLIONS)	184
TABLE 113 HYCAMTIN SALES, 2010-2012 (\$ MILLIONS)	186
TABLE 114 AVASTIN SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	187
TABLE 115 CERVICAL CANCER: TREATMENT OPTIONS, 1999-2008 (%)	189
TABLE 116 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	191
TABLE 117 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	193
TABLE 118 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	194
TABLE 119 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	196
TABLE 120 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, THROUGH 2018 (\$ MILLIONS)	197
TABLE 121 KEY FACTS ABOUT CERVICAL CANCER	198
TABLE 122 CERVICAL CANCER VACCINE PATENTS (%)	201
TABLE 123 CERVICAL CANCER CHEMOTHERAPY DRUGS: PATENT EXPIRY	203



**LIST OF FIGURES**

<b>FIGURE TITLE</b>	<b>PAGE NO.</b>
SUMMARY FIGURE CERVICAL CANCER: GLOBAL MARKET FOR DRUGS AND DIAGNOSTICS, 2012-2018 (\$ MILLIONS)	8
FIGURE 1 MAIN TYPES OF CANCER AND MORTALITY	10
FIGURE 2 CERVICAL CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)	86
FIGURE 3 CERVICAL CANCER: EUROPEAN AGE-STANDARDIZED INCIDENCE RATES PER 100,000 POPULATION AMONG FEMALES, EU27 COUNTRIES, 2008 ESTIMATES	98
FIGURE 4 WORLDWIDE CERVICAL CANCER DIAGNOSTIC MARKET, 2012-2018 (\$ MILLIONS)	125
FIGURE 5 GLOBAL CERVICAL CANCER DIAGNOSTIC TESTS: PAP SMEAR TESTS MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	131
FIGURE 6 WORLDWIDE ESTIMATED NUMBER OF COLPOSCOPY PROCEDURE TESTS PERFORMED, 2012-2018 (MILLIONS)	139
FIGURE 7 CERVICAL CANCER COLPOSCOPY: GLOBAL MARKET AND FORECAST, 2012-2018 (\$ MILLIONS)	140
FIGURE 8 CERVICAL CANCER: COLPOSCOPY TESTS MARKET AND FORECAST IN U.S., 2012-2018 (\$ MILLIONS)	141
FIGURE 9 WORLDWIDE ENDOCERVICAL CURETTAGE (ECC) PROCEDURE MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	144
FIGURE 10 WORLDWIDE HUMAN PAPILLOMAVIRUS (HPV) TESTING MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	146
FIGURE 11 GLOBAL CERVICAL CANCER PROPHYLACTICS MARKET: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	157
FIGURE 12 GLOBAL CERVARIX SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	162
FIGURE 13 GARDASIL SALES AND FORECAST, 2012 AND 2013 (\$ MILLIONS)	163
FIGURE 14 CERVICAL CANCER THERAPEUTIC MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 (\$ MILLIONS)	168
FIGURE 15 GLOBAL CYTOTHERAPEUTICS MARKET, 2010 AND 2017 (\$ MILLIONS)	176
FIGURE 16 U.S. CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	176
FIGURE 17 EUROPEAN CYTOTHERAPEUTICS MARKET, THROUGH 2018 (\$ MILLIONS)	178
FIGURE 18 JAPANESE CYTOTHERAPEUTICS MARKET, 2012-2018 (\$ MILLIONS)	179
FIGURE 19 CERVICAL CANCER MARKET: GLOBAL REVENUE AND FORECASTS, 2012-2018 (\$ MILLIONS)	179
FIGURE 20 CERVICAL CANCER CHEMOTHERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	181
FIGURE 21 CERVICAL CANCER SURGERY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	192
FIGURE 22 SURGERY/HYSTERECTOMY FOR CERVICAL CANCER: GLOBAL SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	193
FIGURE 23 HYSTERECTOMY FOR CERVICAL CANCER IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	194
FIGURE 24 CERVICAL CANCER RADIATION THERAPY MARKET: GLOBAL-SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	196
FIGURE 25 CERVICAL CANCER RADIATION THERAPY MARKET IN U.S.: SALES AND FORECAST, 2012-2018 (\$ MILLIONS)	197